Overview

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

Status:
Active, not recruiting
Trial end date:
2022-06-29
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborators:
Iqvia Pty Ltd
QuintilesIMS